967

CD63

CD63 molecule;CD63;CD63 molecule

CD63 antigen|CD63 antigen (melanoma 1 antigen)|granulophysin|lysosomal-associated membrane protein 3|lysosome-associated membrane glycoprotein 3|melanoma-associated antigen ME491|melanoma-associated antigen MLA1|ocular melanoma-associated antigen|tetraspa

12q12-q13

protein-coding

BACKGROUND: The aim of this study was to clarify the clinical significance of TM4SF members CD9, CD63 and CD82 in human gastric carcinoma. METHODS: By employing RT-PCR and immunohistochemistry, we studied the expression of CD9, CD63 and CD82 in 49 paired tissue specimens of normal gastric mucosa and carcinoma. All tissues were obtained from patients who underwent curative surgery. RESULTS: All normal gastric epithelium and gastric ulcer tissues strongly expressed transcripts and proteins of CD9, CD63 and CD82 as compared with corresponding controls. We found a significant correlation between CD63 mRNA level and different pM statuses (P = 0.036). Carcinomas in M0 stage revealed a stronger expression of CD63 than carcinomas in M1 stage. expression of CD9 protein was found significantly stronger in pN0, pM0 than in advanced pN stages (P = 0.03), pM1 (P = 0.013), respectively. We found the relationship between CD63 expression, gender (p = 0.09) and nodal status (p = 0.028), respectively. Additionally, advanced and metastasized tumor tissues revealed significantly down-regulated CD82 protein expression (p = 0.033 and p = 0, respectively), which correlated with the tumor pTNM stage (p = 0.001). CONCLUSION: The reduction of CD9, CD63 and CD82 expression are indicators for the metastatic potential of gastric carcinoma cells. Unlike their expression in other tumor types, the constitutive expression of CD63 may indicate that this factor does play a direct role in human gastric carcinogenesis.

PURPOSE: To investigate the expression and significance of the proteins and mRNA of metastasis suppressor gene Me491/cd63 and integrin alpha5 in ovarian cancer tissues. METHODS: RT-PCR and in situ hybridization were used to detect the expression of the proteins and mRNA of ME491/CD63 and integrin alpha5 in normal ovarian tissues (Group I), ovarian benign tumor tissues (Group II), ovarian borderline tumor tissues (Group III) and ovarian cancer tissues (Group IV), and the correlation between the expression and the age of patient, degree of differentiation, lymphatic metastasis, stage and pathological type was analyzed. RESULTS: There was a significant change in gene expression between the well and moderately differentiated tumors and poorly differentiated tumors. Gene expression in Groups III and IV was significantly weak, and significantly different from that in Group II and the early-stages of Groups III and IV. There was a significant difference in gene expression between each group. CONCLUSION: There is low expression of the proteins and mRNA of ME491/CD63 and integrin alpha5 in ovarian cancer. The lower the pathological differentiation is, the more significant the loss of expression is and the more likely metastasis is.